Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM (PS-GDM-2022)

Haseki Training and Research Hospital

Status: Completed

Conditions: Gestational Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT05392231

05-2022

Details and patient eligibility

About

The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).

Full description

The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).In this prospective observational study including 109 pregnant women, the fetal pancreas size and maternal serum biomarkers GA and IRAP were measured at the gestational age of 20-22 weeks and later at the gestational age of 24-28 weeks, in 19 participants of them, GDM was confirmed with the 75-g oral glucose tolerance test (OGTT) and the fetal pancreas size was measured in all the participants again.

Enrollment: 109 patients

Sex: Female

Ages: 18 to 42 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Maternal age between 18 and 42 years
• Gestational age between 20 and 28 weeks

Exclusion criteria

• Multiple pregnancies
• Pregestational diabetes
• Fetal congenital malformations
• Placental and amniotic fluid abnormalities
• Preeclampsia
• Severe systemic disease
• Long-term systemic drug usage